Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rotten Rosen Rally?
Wonder if there is any conflicts with presenting at ASCO and where ever they might trying to get the paper published?
Yep they were tracking those tumors too. Correlate that with p21 and the other blood work...published paper anytime imo
TD, I think u hit nail head on that one.
BK that is priceless. I think you should just randomly paste that in to all your posts.
Is Kevetrin nearly expired before it reaches it target? A infusion pump would be more direct than the indirect method they were using in the original phase.
Drip versus pump is indirect to direct?
Wow, love the wording being used in the Kevetrin phase 1 extension! Great find..thanks
I believe Dr.Menon son is named Kevin
Woot, Kevetrin going orphan for pancreatic cancer!
Xoc look at the 10/26/2015 PR the one you cite is more preclinical in 2011.
TD, hopefully the extension of the phase 1 Kevetrin trial at Harvard is for testing out multi-dosing Kevetrin weekly. Its something the company has been talking about for years. Leo already stated that they are not sure at what phase of the cell cycle Kevetrin will be most effective at. Multi-dosing could shed some light here and confirm what direction they want to take in the phase 2's.
Get FDA approval for modifying the protocol and have the safety board approve it and you already have everything else in place.
Amen to that Mr.NR
I agree with this constantly holding out to "maximize" share holder value in the future negates the present time too much. One of those things I wish the company would do is look from the outside in instead of always looking inside out.
In the real world the lead plantiff should suing Rosen not have Rosen represent him.
Poor Mr.Kim he cannot even use the Harvard excuse.
Prurisol, active but not recruiting. Enrollment Complete!
https://clinicaltrials.gov/ct2/results?term=Cellceutix&Search=Search
Great point BK!
With operating history now satisfied with 2years of audited 10k's. And sufficient funds for the next year. I believe all we need to do is hold $2+ for 5days to qualify for Nasdaq global market.
Have to wonder how much Dr. Reddy's situations hampered Prurisol but should not impede Kevetrin or Brilacidin. The only other work they are doing is the formulation work on B-optic, I believe
The company has all the information on Kevetrin phase 1 now but the proper way to convey to the information to the medical community and investors is through a peered review publication which now in progress. DF is not in charge now the norms are.
If that was true why didn't the company do retino ped. years ago? Something was proven in kevetrin phase 1 that allowed for them to move forward only now. Efficacy in humans and p53 activation....proof of concept.
Should only be 1 paper on Kevetrin phase 1 with multiple authors Menon and Shapiro and many others. One cannot really write more than one research paper of this nature, facts are facts and not open to literary styling. The article could be submitted to multiple venues though.
Thanks. I had my west coast early morning goggles on when I read it.
How do we know that is not Kevetrin?
That is a wow.
Thanks F1ash and LR the FDA pediatric voucher system almost seems backwards awarding it only after the drug is approved but I suppose if the drug is awarded orphan drug status during development it is essentially awarded the same benefits at that time.
Thanks F1ash, I will check it out
Anyone have a feel for how the process works with the FDA pedriatric voucher. We appear to be fully qualified for it now but in what step of the process does the FDA actually award it to the compnay?
Leo runs the company and so many trials on so little money it would be interesting to see what he could do with 300 million. The rough value of the voucher if sold.
Go Voucher! Go Voucher!
I dont see it happening but like I said I hope your right it would be nice. The company has much bigger catalyst looming.
F1ash, I hope your right about a reverse in price on the Rosen lawsuit being dropped but like I said I think everyone already knows that the whole Rosen/Mako fiasco is a joke now so why hasn't the price recovered? Rosen has been doing what they do for a long time they have no credibility so them dropping the charges should have only a minimal impact. And we have seen the sad attempts of Mako trying to take down other legitimate companies with little effect. Ashcroft already vetted the company when it took up CTIX's case not that I felt the company needed to be vetted anyways at least not in that fashion.
I think one has to look more at the fundamental problem of the situation. The price should have not have dropped the way it did when this whole thing started. I doubt Mako aggressively shorting or monkeying around in the pre-market drove down the price all upon itself. But what it did do was give a clear sell signal to the retail flippers and the "money managers". While I read the Mako report on the day it was published I honestly laughed out loud and didn't even think about selling a single share. But to others who perhaps laughed out loud as well it was a clear selling point. And why wouldn't it be? -I guess.
I also believe many that sold on that day have already gotten back in to the CTIX stock at these new low prices and have been able to do so without driving the price backup and are currently just flipping the price around in the 1.30-1.50 range. I don't think there is too many investors sitting on the side lines waiting for that ridiculous Rosen lawsuit to be dropped to buy back in.
Ironically, about a month ago I posted that I thought "sadly" that the next big catalyst for CTIX was the actual dropping of the lawsuit but watching the actual price and volume over the last ~30 days makes me think we obtained a new trading level and the stock is back to being flipped at this new range by our original usual suspects.
Having said that I am very excited about the companies future. I think we are about to get a whole lot of Kevetrin catalysts in the coming weeks and months. Its a mystery as to why this company has such a poor valuation at this point and time. I don't care if the mystery will ever be solved because I know it will be corrected at some point.
What white collar crime doesn't matter anymore? Mako trimmed 100 million off our market cap. He should be in jail. Rosen doesn't have cash and their lawsuit to me means little Rosen is ambulance chasers. If one is worried about press here go after all the questionable law firms fishing for class action. Rosen dropping the lawsuit should mean little to our current market cap. Most investors understand what Rosen is.
Not sure why but they seem to want to target Rosen more while the real damage was done by Mako.
I wish we did have the short interest that you think we do but sadly we dont.
Post operative preventive treatment if the cornea was breached? I guess I don't see an issue with not being able to permeate the cornea. Were not trying to replace Visine if you have an infection within the cornea certain steps would have to be taken anyways.
Expect Kevetrin data soon. Leo has been gnawing on his arm to get those Harvard schakles off for a few years. No doubt he is bringing that data out ASAP.
Couldn't they just inject it through the cornea?
UofB is now a great partnering opportunity for CTIX
Thought Aruda had 8 million. If your going for tax loss you should have sold already you don't have to wait till Dec 31. Merck is running out of money! Yeah no rs! And not everyone here is a flipper.
U of B does suck it will be interesting to see how the company handles it.
Biggest catalyst in the companies history is coming at anytime! Kevetein!
I agree dang traders can't go too much more than a couple dimes before selling off. Get a job already!